Early trial backs use of artificial skin tissue

The UK's Intercytex has unveiled new early-stage data that supports its contention that an experimental artificial skin can reduce scarring. ICX-SKN is based on proteins found in wounds undergoing the healing process. Researchers have added fibroblasts to manufacture tissue that closely replicates the body's mechanism for developing new skin. The lab-made tissue was fully integrated in volunteers in 28 days. Squares of skin were cut from the bodies of six volunteers and replaced with the artificial tissue in the trial.

- read the Cosmetics Design report

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.